AGC Pharma Chemicals to boost capacity by 30% at Spanish site

The expansion will increase production capacity for synthetic pharmaceutical products

The CDMO, a subsidiary of Tokyo-based AGC Inc, says the new 7,500 m2 facility is scheduled to begin operation in the first half of 2024, with an estimated total investment of $100 million. This is expected to add 100 new jobs.  

The expansion will include the introduction of facilities for highly potent active pharmaceutical ingredients (HPAPI), with the company noting increased demand for such ingredients in recent years.  

This comes after AGC increased production capacity and built a new R&D facility at the same site, which also serves as the CDMO’s headquarters, in 2020.   

AGC says it is considering additional capacity expansion in the near future, adding that the new facility will have the space to accommodate the undisclosed project.  

AGC Pharma Chemicals Europe was acquired from Boehringer Ingelheim in March 2019 as part of AGC’s drive to establish synthetic pharmaceutical production capability in Europe.  

In October of the same year, the name was changed from Malgrat Pharma Chemicals to its current AGC Pharma Chemicals Europe.